Our associate in the U.K., Potter Clarkson, prepared the following explanation of why there is an advantage, once a European Patent is granted, to perfecting coverage in most, if not all, of the member countries. We felt that the information should be passed on to our clients as well.
“All of the European Union (EU) countries (plus various others) can be designated on an EPO application, on payment of appropriate fees. When a patent is granted, the applicant must decide the countries in which to process the patent. Clients are sometimes concerned about the effect of not having patent protection in all of the EU countries.
The basic position is that a patent in a given EU country, if it is valid and infringed by the product in question, can be used to prevent not only unauthorised manufacture in that country but also unauthorised imports from another country (whether part of the EU or not). However, products that are put on the market in any EU country by, or with the consent of, the patent proprietor are regarded as being “authorised” and may thereafter move freely within the EU.
This is illustrated by the following scenario:
The EPO patent is processed into Germany but not Greece. In Greece, competitors can therefore sell the product. They may do so at a lower price than the patentee would charge. In order to compete in that country, the patentee has to lower his prices. In Germany, however, where the market is protected by the patent, the patentee can charge a higher price.
The EU rules concerning exhaustion of rights mean that the patentee cannot then prevent his own low-priced product being bought in Greece and shipped to Germany and thus effectively competing with his higher-margin product in that country.
He can, however, as noted above, prevent the competitor’s product being imported into Germany. In addition, the potential impact on the German profit margins can be avoided if the patentee chooses not to sell his own product in Greece.
In summary, therefore, the disadvantage of not pursuing patent protection in all EU countries (apart from the obvious one of not being able to prevent local competition in the countries without a patent) is that it can hinder one’s ability to charge different prices in different parts of the EU market for the same product.
N.B. This is a simplified review of the situation, applicable to most inventions, and intended specifically to help our clients decide the countries into which to process a granted EPO patent. It is not intended to be a comprehensive account of the concept and practice of the exhaustion of IP rights and, in particular, it does not address global issues. In addition, special factors can influence particular products, for example medicines, the price of which may be governed at least in part by national health authorities.
Clients should ask us for specific advice on any particular situation that affects them”.
Tom Nikolai (612) 392-7307 Tom.Nikolai@nm-iplaw.com